Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as ...

In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer (PFE) and BioNTech (BNTX) lose bid to appeal a High Court ruling that issued Moderna (MRNA) a COVID-19 vaccine patent ...

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Shares of Pfizer Inc. PFE slid 2.18% to $23.29 Thursday, on what proved to be an all-around dismal trading session for the ...

Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the ...

This was the stock's third consecutive day of losses.